Who is sponsoring NCT03654924?

NCT03654924 is sponsored by National University Hospital, Singapore.

What drugs are being tested in NCT03654924?

Interventions in NCT03654924: Laryngeal Mask.

What condition does NCT03654924 study?

NCT03654924 studies Value of Continuous Pressure Monitoring in Laryngeal Mask.

Is NCT03654924 still recruiting?

NCT03654924 is currently completed. Last updated 30 March 2020.

Last reviewed 2020-03-30 · How we verify

NCT03654924

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Continuous Laryngeal Cuff Pressure Monitoring

Completed NA Last updated 30 March 2020

What this trial tests

NA trial testing Laryngeal Mask in Value of Continuous Pressure Monitoring in Laryngeal Mask in 51 participants. Completed in 25 July 2019.

Timeline

1 September 2016

Primary endpoint
25 July 2019

25 July 2019

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	51
Start date	1 September 2016
Primary completion	25 July 2019
Estimated completion	25 July 2019
Sites	1 location across Singapore

Drugs / interventions tested

Laryngeal Mask

Conditions studied

Value of Continuous Pressure Monitoring in Laryngeal Mask — all drugs for Value of Continuous Pressure Monitoring in Laryngeal Mask →

Sponsor

National University Hospital, Singapore

Who can join

18 and older, any sex, with Value of Continuous Pressure Monitoring in Laryngeal Mask. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the airway seal of LMA during intraoperative manipulation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other National University Hospital, Singapore trials

Trials by the same sponsor.

NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03654924 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
Last refreshed: 30 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03654924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing